SCHEMBL14075422

SCHEMBL14075422

O=C(Nc1ccc(Cc2ccc(NC(=O)c3ccccc3)c(C(=O)O)c2)cc1C(=O)O)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTC4S Q16873 1/20 1.00
MEN1 O00255 5/20 0.66
KMT2A Q03164 5/20 0.66
MAPT P10636 4/20 0.66
PKM P14618 3/20 0.66
TDP1 Q9NUW8 3/20 0.66
GRIK1 P39086 1/20 0.66
MCL1 Q07820 1/20 0.61
BCL2A1 Q16548 1/20 0.61
SERPINE1 P05121 4/20 0.59
KDM4E B2RXH2 1/20 0.58
GFER P55789 1/20 0.56
DHODH Q02127 1/20 0.53
ALDH1A1 P00352 2/20 0.52
HTT P42858 1/20 0.52
AKR1C4 P17516 2/20 0.52
AKR1C3 P42330 2/20 0.52
AKR1C2 P52895 2/20 0.52
AKR1C1 Q04828 2/20 0.52
ABL1 P00519 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14075299 0.91 LTC4S (0.84) LTC4SMEN1KMT2AMAPTPKM
SCHEMBL29472419 0.91 LTC4S (0.84) LTC4SMEN1KMT2AMAPTPKM
SCHEMBL19425638 0.86 LTC4S (0.75) LTC4SMEN1KMT2AMAPTPKM
SCHEMBL14075312 0.86 LTC4S (0.75) LTC4SMEN1KMT2AMAPTPKM
SCHEMBL14087681 0.86 LTC4S (0.75) LTC4SMEN1KMT2AMAPTPKM
SCHEMBL14075178 0.85 LTC4S (0.73) LTC4SPKMKDM4EGFERTSHR
SCHEMBL2271422 0.85 LTC4S (0.74) LTC4SMEN1KMT2AMAPTPKM
SCHEMBL14413321 0.85 LTC4S (0.72) LTC4SSERPINE1DHODHALDH1A1
SCHEMBL14075294 0.84 LTC4S (0.72) LTC4SMEN1KMT2AMAPTPKM
SCHEMBL14075191 0.83 LTC4S (0.69) LTC4SMEN1KMT2AMAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160067257-A1 SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY THE WISTAR INSTITUTE (US) 2016-03-10 US disclosed
US-9234230-B2 Screening method and compounds for modulating telomerase activity THE WISTAR INSTITUTE (US) 2016-01-12 US disclosed
US-20120309759-A1 Screening Method and Compounds for Modulating Telomerase Activity THE WISTAR INSTITUTE (US) 2012-12-06 US disclosed
US-7429677-B2 Small molecule entry inhibitors TIBOTEC PHARMACEUTICALS LTD. (IE) 2008-09-30 US disclosed
US-7429677-B2 Small molecule entry inhibitors TIBOTEC PHARMACEUTICALS LTD. (IE) 2008-09-30 US disclosed
US-7264932-B2 Nuclease inhibitor cocktail APPLERA CORPORATION (US) 2007-09-04 US disclosed
US-7264932-B2 Nuclease inhibitor cocktail APPLERA CORPORATION (US) 2007-09-04 US disclosed
US-20070032418-A1 Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same AMBION, INC (US) 2007-02-08 US disclosed
US-20070032418-A1 Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same AMBION, INC (US) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032418-A1 Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same RNASE1, RNASEH1, RNASEL LTC4S 2560/4885MEN1 2073/4885KMT2A 2728/4885
US-20120309759-A1 Screening Method and Compounds for Modulating Telomerase Activity TERT, TERB1, TERF2 LTC4S 2799/4885MEN1 3807/4885KMT2A 2921/4885
US-20160067257-A1 SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY TERT, TERB1, TERF2 LTC4S 2799/4885MEN1 3807/4885KMT2A 2921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.